Spero Therapeutics, Inc. News - SPRO

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
LEVEL 1 STARTER
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN
Spero Therapeutics, Inc. SPRO NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.36 3.01% 12.33 12.50 12.00 12.26 11.97 15:59:55
more quote information »

Recent News

Date Time Source Heading
6/17/201908:30GLOBESpero Therapeutics to Present Data for All Pipeline Programs..
6/14/201906:01EDGARProspectus Filed Pursuant to Rule 424(b)(5) (424b5)
6/13/201908:14EDGARCurrent Report Filing (8-k)
6/13/201908:00GLOBESpero Announces $10 Million Registered Direct Offering of..
6/06/201916:41EDGARCurrent Report Filing (8-k)
6/05/201918:55EDGARStatement of Changes in Beneficial Ownership (4)
6/05/201918:54EDGARStatement of Changes in Beneficial Ownership (4)
6/05/201918:51EDGARStatement of Changes in Beneficial Ownership (4)
6/05/201918:50EDGARStatement of Changes in Beneficial Ownership (4)
6/05/201918:48EDGARStatement of Changes in Beneficial Ownership (4)
6/05/201918:47EDGARStatement of Changes in Beneficial Ownership (4)
5/31/201917:00GLOBESpero Therapeutics Announces Inducement Grants Under Nasdaq..
5/09/201916:18EDGARCurrent Report Filing (8-k)
5/09/201916:10GLOBESpero Therapeutics Announces First Quarter 2019 Operating..
5/09/201916:03EDGARQuarterly Report (10-q)
5/01/201908:00GLOBESpero Therapeutics Announces Inducement Grants Under Nasdaq..
4/26/201916:34EDGARProxy Statement (definitive) (def 14a)
4/18/201917:04EDGARCurrent Report Filing (8-k)
4/08/201908:30GLOBESpero Therapeutics Highlights SPR994 Data at the 29th..
4/01/201915:14EDGARConfidential Treatment Order (ct Order)
3/29/201919:30EDGARStatement of Changes in Beneficial Ownership (4)
3/29/201916:55EDGARAmended Current Report Filing (8-k/a)
3/29/201908:00GLOBESpero Therapeutics Receives FDA Fast Track Designation for..
3/19/201917:30EDGARInitial Statement of Beneficial Ownership (3)
3/19/201908:12EDGARCurrent Report Filing (8-k)
3/19/201908:00GLOBESpero Announces Appointment of Cynthia Smith to its Board of..
3/14/201916:55EDGARSecurities Registration: Employee Benefit Plan (s-8)
3/14/201916:51EDGARSecurities Registration: Employee Benefit Plan (s-8)
3/14/201916:13EDGARCurrent Report Filing (8-k)
3/14/201916:10BWSpero Therapeutics Announces Fourth Quarter and Full Year..
3/14/201916:06EDGARAnnual Report (10-k)
3/01/201908:30GLOBESpero Therapeutics to Present at March Investor Conferences
2/26/201908:00GLOBESpero Therapeutics Receives QIDP Designation from the U.S...
2/14/201918:31EDGARAmended Statement of Ownership (sc 13g/a)
2/14/201917:15EDGARAmended Statement of Ownership (sc 13g/a)
2/14/201916:59EDGARAmended Statement of Ownership (sc 13g/a)
2/13/201912:13EDGARAmended Statement of Ownership (sc 13g/a)
2/08/201906:21EDGARAmended Statement of Ownership (sc 13g/a)
2/04/201907:00GLOBESpero Therapeutics Announces FDA Acceptance of IND..
1/29/201908:00GLOBESpero Therapeutics Announces Initiation of SPR720 Phase 1..
1/07/201917:02EDGARCurrent Report Filing (8-k)
1/07/201916:01GLOBESpero Therapeutics Signs License Agreement with Everest..
1/07/201907:30GLOBESpero Therapeutics Announces Positive Feedback from FDA..
12/12/201806:02EDGARNotice of Effectiveness (effect)
12/11/201810:32EDGARConfidential Treatment Order (ct Order)
12/03/201817:20EDGARSecurities Registration Statement (simplified Form) (s-3)
11/16/201809:03EDGARCurrent Report Filing (8-k)
11/13/201808:48EDGARCurrent Report Filing (8-k)
11/08/201816:18EDGARCurrent Report Filing (8-k)
11/08/201816:10GLOBESpero Therapeutics Announces Third Quarter 2018 Financial..
See more news about this stock »


Your Recent History
NASDAQ
SPRO
Spero Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.